Blog
RSS FeedPosted by Michael Wonder on 01 Nov 2023
Epcoritamab for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments
1 November 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 01 Nov 2023
Cabozantinib maleate for previously treated adults with advanced differentiated thyroid cancer that is unsuitable for or refractory to radioactive iodine
1 November 2023 - NICE has published final evidence-based recommendations on the use of cabozantinib maleate (Cabometyx) for previously treated ...
Posted by Michael Wonder on 25 Oct 2023
Daratumumab in combination with lenalidomide and dexamethasone for untreated patients with multiple myeloma who are ineligible for stem cell transplantation
25 October 2023 - NICE has published final evidence-based recommendations on the use of daratumumab (Darzalex) in combination with lenalidomide ...
Posted by Michael Wonder on 24 Oct 2023
Abiraterone: thousands of men miss out on life-extending prostate cancer drug
24 October 2023 - Thousands of patients in England and Northern Ireland are missing out on a life-extending prostate cancer ...
Posted by Michael Wonder on 21 Oct 2023
Brukinsa receives positive recommendation from NICE in the UK for adult patients with chronic lymphocytic leukaemia
20 October 2023 - BeiGene today announced that NICE of the United Kingdom has issued a final draft guidance recommending ...
Posted by Michael Wonder on 19 Oct 2023
Tabelecleucel for the treatment of patients with a post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus
19 October 2023 - NICE is unable to make a recommendation on the use of tabelecleucel (Ebvallo) for the treatment of ...
Posted by Michael Wonder on 17 Oct 2023
First treatment to be recommended by NICE at the same time it is approved for advanced lymphoma in the UK
17 October 2023 - More than 700 people set to benefit from new treatment option for advanced lymphoma. ...
Posted by Michael Wonder on 17 Oct 2023
Glofitamab for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments
17 October 2023 - NICE has published final evidence based recommendations on the use of glofitamab (Columvi) for the treatment ...
Posted by Michael Wonder on 03 Oct 2023
Loncastuximab tesirine for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments
3 October 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 26 Sep 2023
NICE draft guidance recognises potential of new targeted treatment for type of advanced breast cancer
26 September 2023 - NICE has today published draft guidance for public consultation that does not recommend trastuzumab deruxtecan for ...
Posted by Michael Wonder on 20 Sep 2023
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency
20 September 2023 - NICE has published evidence-based recommendations on the use of pembrolizumab (Keytruda) for the adults with previously ...
Posted by Michael Wonder on 17 Aug 2023
Keytruda backed for 'basket' of new cancers via NHS
17 August 2023 - The UK's cost effectiveness agency NICE has recommended MSD's PD-1 inhibitor Keytruda for a series of ...
Posted by Michael Wonder on 01 Aug 2023
Zanubrutinib for the treatment of patients with chronic lymphocytic leukaemia
1 August 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 28 Jul 2023
Talazoparib tosylate for the treatment of patients with advanced, germline BRCA mutation positive, HER2 negative breast cancer
28 July 2023 - NICE has published preliminary evidence-based recommendations on the use of talazoparib tosylate (Talzenna) for the treatment of ...
Posted by Michael Wonder on 26 Jul 2023
Selpercatinib for untreated RET fusion positive advanced non-small-cell lung cancer
26 July 2023 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for adults with advanced, ...